Joseph Ciccolini

Marseille, France

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 135 publications

Correction to: The CetuxIMAX study: a population pharmacokinetic approach to modelling the pharmacokinetics and pharmacodynamics relationships of Cetuximab in patients with head and neck cancer.

Correction to: The CetuxIMAX study: a population pharmacokinetic approach to modelling the pharmacokinetics and pharmacodynamics relationships of Cetuximab in patients with head and neck cancer.

Journal: Cancer chemotherapy and pharmacology
Published: July 18, 2026

The CetuxIMAX study: a population pharmacokinetic approach to modelling the pharmacokinetics and pharmacodynamics relationships of Cetuximab in patients with head and neck cancer.

The CetuxIMAX study: a population pharmacokinetic approach to modelling the pharmacokinetics and pharmacodynamics relationships of Cetuximab in patients with head and neck cancer.

Journal: Cancer chemotherapy and pharmacology
Published: January 12, 2026

Bringing 5-FU monitoring home: microsampling as the potential next step beyond DPD deficiency screening.

Bringing 5-FU monitoring home: microsampling as the potential next step beyond DPD deficiency screening.

Journal: Expert opinion on drug metabolism & toxicology
Published: January 08, 2026

Dihydropyrimidine Dehydrogenase-Guided Dosing of 5-Fluorouracil: Prioritizing Precision Over Dose Reduction.

Dihydropyrimidine Dehydrogenase-Guided Dosing of 5-Fluorouracil: Prioritizing Precision Over Dose Reduction.

Journal: JCO precision oncology
Published: October 02, 2025

Antibody drug conjugates: Use and optimization in HER2-negative metastatic breast cancers (triple negative, RH+/HER2-)

Antibody drug conjugates: Use and optimization in HER2-negative metastatic breast cancers (triple negative, RH+/HER2-)

Journal: Bulletin du cancer
Published: July 26, 2025

Eco Friendly and Budget Smart: An Economic and Environmental Evaluation of Alternative PD-1 and PD-L1 Inhibitor Dosing Regimens.

Eco Friendly and Budget Smart: An Economic and Environmental Evaluation of Alternative PD-1 and PD-L1 Inhibitor Dosing Regimens.

Journal: PharmacoEconomics
Published: April 19, 2025

Pharmacology and pharmacokinetics of antibody-drug conjugates, where do we stand?

Pharmacology and pharmacokinetics of antibody-drug conjugates, where do we stand?

Journal: Cancer treatment reviews
Published: January 24, 2025

Impact of CDA Dynamics on Clinical Outcome of Patients With AML or High-Risk MDS Treated With Nucleoside Analogs.

Impact of CDA Dynamics on Clinical Outcome of Patients With AML or High-Risk MDS Treated With Nucleoside Analogs.

Journal: Hematological oncology
Published: December 23, 2024

Predicting the toxicity-efficacy ratio of venetoclax in real-world patients.

Predicting the toxicity-efficacy ratio of venetoclax in real-world patients.

Journal: Annals of hematology
Published: December 09, 2024

DPD Ultra-Rapid Metabolizer Status and Efficacy of 5-Fluorouracil Treatment: A Real-World Study.

DPD Ultra-Rapid Metabolizer Status and Efficacy of 5-Fluorouracil Treatment: A Real-World Study.

Journal: Fundamental & clinical pharmacology
Published: December 08, 2024

Body mass index affects imatinib exposure: Real-world evidence from TDM with adaptive dosing.

Body mass index affects imatinib exposure: Real-world evidence from TDM with adaptive dosing.

Journal: Fundamental & clinical pharmacology
Published: July 24, 2024

Adaptive dosing of high-dose busulfan in real-world adult patients undergoing haematopoietic cell transplant conditioning.

Adaptive dosing of high-dose busulfan in real-world adult patients undergoing haematopoietic cell transplant conditioning.

Journal: British journal of clinical pharmacology
Published: June 15, 2024
Showing 1-12 of 135

Last Updated: 09/26/2026